कंपनी का अवलोकन
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology entity within the United States, primarily dedicated to the advancement of NDV-01, a controlled-release intravesical formulation combining gemcitabine and docetaxel. This formulation is currently undergoing Phase 2 clinical trials specifically for patients suffering from aggressive forms of non-muscle invasive bladder cancer. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, where the primary objective is the discovery and development of novel therapeutic agents rather than immediate large-scale commercialization. Relmada maintains a market capitalization of $733.18M while employing a workforce of 17 individuals, indicating a lean operational structure typical of early-stage biotech firms. The absence of reported annual revenue in the trailing twelve months suggests that the company is still in the investment phase of its development lifecycle, where capital is directed toward clinical progression rather than sales generation. This specific market positioning implies that the $733.18M valuation reflects the potential future value of the clinical asset pipeline rather than current cash-flow-generating operations. The small employee base relative to the market cap highlights the high concentration of expertise required to manage complex clinical trials and regulatory submissions without a large administrative overhead. Consequently, the company's scale is defined by its reliance on external funding to bridge the gap between pre-commercial clinical data and potential market entry.
वित्तीय स्वास्थ्य
The reported net income for the trailing twelve months stands at $-15,005,199, while the EBITDA figure is recorded at $-13,855,048, both reflecting significant operational losses inherent to the clinical development stage. The revenue for the trailing twelve months is listed as N/A, which creates a substantial gap between nominal revenue and net income, revealing a cost structure dominated by research and development expenditures, clinical trial costs, and regulatory filing fees. The free cash flow is reported at $-7,737,662, indicating a continuous cash burn rate that necessitates regular capital raising to sustain operations and fund ongoing clinical programs. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for companies that have not yet generated commercial sales or where revenues do not exceed the associated costs. The company holds a cash reserve of $116.44M against total debt of $110,247, resulting in a debt-to-equity ratio of 0.10, which suggests a highly conservative balance sheet with minimal leverage. The current ratio is exceptionally high at 80.21, signaling robust short-term liquidity and an abundant ability to meet obligations due within one year using existing current assets. Return on Equity is -25.6% and Return on Assets is -14.4%, metrics that indicate the management team is currently deploying capital to generate negative returns in pursuit of future clinical milestones. These negative return figures are typical for clinical-stage entities where the primary goal is asset preservation and pipeline advancement rather than shareholder profit maximization.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to the absence of positive earnings, while the forward P/E is listed as -17.05, a metric that implies the market is pricing in future earnings potential that has not yet materialized in the current financial statements. The price-to-book ratio stands at 5.92, indicating that the market values the company at nearly six times its book value, which often reflects the high intrinsic value placed on the intellectual property and the potential success of the clinical asset NDV-01. The price-to-sales ratio is N/A because there is no reported sales revenue, while the EV/EBITDA ratio is 2.65, a metric that remains low due to the negative earnings base but provides an alternative perspective on the enterprise value relative to operating profitability. The stock has traded between a 52-week low of $0.24 and a 52-week high of $7.51, creating a range of $7.27 in which the current price point must be situated relative to historical volatility. The beta is listed as N/A, suggesting that there is insufficient historical data or standard deviation calculated to determine the stock's price volatility relative to the broader market index. These valuation metrics collectively present a high-risk profile where the enterprise value is driven by the probability of clinical success rather than traditional earnings multiples. The forward P/E of -17.05 further underscores that the stock is not currently supported by earnings power but rather by speculative expectations regarding the drug's approval and commercial launch.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is also N/A, as the company has not yet established a consistent track record of commercial sales or profitable operations to support growth rate calculations. The absence of positive earnings means that earnings are not growing faster or slower than revenue in the traditional sense, as both metrics are currently undefined or negative. Relmada does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company retains all available capital to reinvest into its clinical trials and operational infrastructure. This reinvestment strategy is standard for clinical-stage biotechnology firms that prioritize accelerating the development pipeline over distributing income to shareholders. The overall growth and income profile is characterized by a complete reliance on capital markets for funding, with no current income generation or historical growth data to evaluate past performance.